Dolores J. Schendel

Chief Executive & Scientific Officer at MediGene AG

Dolores J. Schendel

Dolores J. Schendel

Chief Executive & Scientific Officer at MediGene AG

Overview
Career Highlights

MediGene AG

RelSci Relationships

148

Number of Boards

2

Relationships
RelSci Relationships are individuals Dolores J. Schendel likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Financial Officer & Chief Business Development Officer at MediGene AG

Relationship likelihood: Strong

Chief Medical Officer & Chief Development Officer at MediGene AG

Relationship likelihood: Strong

Scientific Director at Baygene

Relationship likelihood: Strong

General Secretary at Internat Human Frontier Science Programm

Relationship likelihood: Strong

Managing Director at Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft

Relationship likelihood: Strong

Treasurer & Non-Executive Director at Biohealth Innovation, Inc.

Relationship likelihood: Strong

Founder at Wellington Partners GmbH

Relationship likelihood: Strong

Chief Financial Officer at InflaRx NV

Relationship likelihood: Strong

Chief Executive Officer at Rentschler Biotechnologie GmbH

Relationship likelihood: Strong

Former Chief Executive Officer at Intercell USA, Inc.

Relationship likelihood: Strong

Paths to Dolores J. Schendel
Potential Connections via
Relationship Science
You
Dolores J. Schendel
Chief Executive & Scientific Officer at MediGene AG
Education

The University of Wisconsin–Madison has long been recognized as one of America's great universities. A public, land-grant institution, UW–Madison offers a complete spectrum of liberal arts studies, professional programs and student activities. Spanning 936 acres along the southern shore of Lake Mendota, the campus is located in the city of Madison.

Career History
Chief Executive & Scientific Officer
2014 - Current

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.

Managing Director
2014 - Prior

Medigene Immunotherapies GmbH, a subsidiary of MediGene AG, is a company headquartered in Planegg, Germany, that develops immunotherapy to treat cancer. The firm was founded in 2013 by Dolores J. Schendel and Thomas Blankenstein. Axel-Sven Malkomes is currently the CEO of the company. On 27 Jan 14 MediGene AG acquired Medigene Immunotherapies GmbH for $13.05 million.The company says this about itself: Based on more than 15 years of extensive research in the field of immunotherapy, Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH) was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100%subsidiary in January 2014. Medigene Immunotherapies pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC)vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.

Professor
Prior

Ludwig-Maximilians-Universität München is a premier academic and research institutions.

Investments
Details Hidden

Medigene Immunotherapies GmbH, a subsidiary of MediGene AG, is a company headquartered in Planegg, Germany, that develops immunotherapy to treat cancer. The firm was founded in 2013 by Dolores J. Schendel and Thomas Blankenstein. Axel-Sven Malkomes is currently the CEO of the company. On 27 Jan 14 MediGene AG acquired Medigene Immunotherapies GmbH for $13.05 million.The company says this about itself: Based on more than 15 years of extensive research in the field of immunotherapy, Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH) was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100%subsidiary in January 2014. Medigene Immunotherapies pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC)vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.

Details Hidden

DJSMontana Holding GmbH is a German company that provides investements services.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Dolores J. Schendel. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Dolores J. Schendel's profile does not indicate a business or promotional relationship of any kind between RelSci and Dolores J. Schendel.